


[Figure 1]


100
50
0
T/C (%)
*
TS-1
TS-1 + compound 6
TS-1 + compound 4
TS-1 + compound 7
TS-1 + compound 8
TS-1 + compound 19
TS-1 + compound 9
TS-1 + compound 2
TS-1 + compound 1
TS-1 + comparative compound 1


[Figure 2]


100
50
0
T/C (%)
*
*
*
*
*
*
TS-1
TS-1 + compound 5
TS-1 + compound 14
TS-1 + compound 3
TS-1 + compound 15
TS-1 + compound 16
TS-1 + compound 17


[Figure 3]



100
50
0
T/C (%)
*
5-FU
5-FU + compound 1
5-FU + compound 2
5-FU + compound 5
5-FU + compound 15
5-FU + compound 16
5-FU + compound 17
5-FU + compound 18
5-FU + compound 9

[Figure 4]



100
50
0
T/C (%)
*
Capecitabine
Capecitabine + compound 2
Capecitabine + compound 1
Capecitabine + compound 13
FdUrd
FdUrd + compound 2
Pemetrexed
Pemetrexed + compound 2
Pemetrexed + compound 1
Pemetrexed + compound 13
UFT
UFT + compound 2

[Figure 5]



SC-6
Body Weight change (%)
20
10
0
-10
-20
-30
0
5
10
15
Days
Control
TS-1
TS-1 + comp. 2


SC-6
Relative Tumor Volume
10
8
6
4
2
0
0
5
10
15
Days
*
Control
TS-1
TS-1 + comp. 2


[Figure 6]


LS174T
Body Weight Change (%)
20
10
0
-10
-20
-30
0
5
10
15
Days
Control
TS-1
TS-1 + Comp.2
LS174T
Relative Tumor Volume
13
10
8
5
3
0
0
5
10
15
Days
*
Control
TS-1
TS-1 + Comp.2


[Firure 7]


CFPAC-1
Body Weight Change (%)
20
10
0
-10
-20
-30
0
5
10
Days
Control
TS-1
TS-1 + Comp.2
CFPAC-1
Relative Tumor Volume
3.5
3
2.5
2
1.5
1
0.5
0
0
5
10
15
Days
*
Control
TS-1
TS-1 + Comp.2


[Figure 8]


20
15
10
5
0
Relative tumor volume
Control
Compound 2(1200)
0
150
300
600
1200
TS-1(8.3) + Compound 2


[Figure 9]


100.0
10.0
1.0
0.1
Relative tumor volume
0
10
20
30
Days
**
**
**
Control
TS-1(18)
TS-1(18)+Compound 2(6.25)
TS-1(18)+Compound 2(12.5)
TS-1(18)+ Compound 2(25)
TS-1(18)+Compound 2(50)
TS-1(18)+Compound 2(100)


[Figure 10]


Relative tumor volume
Days
Control
Capecitabine(160)
Capecitabine(160) + Comp.2(600)
Capecitabine(160) + Comp.2(1200)
Capecitabine(160) + Comp.2(1600)
Capecitabine(359)
Capecitabine(359) + Comp.2(75)
Capecitabine(359) + Comp.2(300)
Capecitabine(359) + Comp.2(600)
Capecitabine(809)
Capecitabine(809) + Comp.2(75)


[Figure 1]


100
50
0
T/C (%)
*
TS-1
TS-1 + compound 6
TS-1 + compound 4
TS-1 + compound 7
TS-1 + compound 8
TS-1 + compound 19
TS-1 + compound 9
TS-1 + compound 2
TS-1 + compound 1
TS-1 + comparative compound 1


[Figure 2]


100
50
0
T/C (%)
*
*
*
*
*
*
TS-1
TS-1 + compound 5
TS-1 + compound 14
TS-1 + compound 3
TS-1 + compound 15
TS-1 + compound 16
TS-1 + compound 17


[Figure 3]



100
50
0
T/C (%)
*
5-FU
5-FU + compound 1
5-FU + compound 2
5-FU + compound 5
5-FU + compound 15
5-FU + compound 16
5-FU + compound 17
5-FU + compound 18
5-FU + compound 9

[Figure 4]



100
50
0
T/C (%)
*
Capecitabine
Capecitabine + compound 2
Capecitabine + compound 1
Capecitabine + compound 13
FdUrd
FdUrd + compound 2
Pemetrexed
Pemetrexed + compound 2
Pemetrexed + compound 1
Pemetrexed + compound 13
UFT
UFT + compound 2


[Figure 5]


SC-6
Body Weight change (%)
20
10
0
-10
-20
-30
0
5
10
15
Days
Control
TS-1
TS-1 + comp. 2



SC-6
Relative Tumor Volume
10
8
6
4
2
0
0
5
10
15
Days
*
Control
TS-1
TS-1 + comp. 2


[Figure 6]


LS174T
Body Weight Change (%)
20
10
0
-10
-20
-30
0
5
10
15
Days
Control
TS-1
TS-1 + Comp.2



LS174T
Relative Tumor Volume
13
10
8
5
3
0
0
5
10
15
Days
*
Control
TS-1
TS-1 + Comp.2

[Firure 7]



CFPAC-1
Body Weight Change (%)
20
10
0
-10
-20
-30
0
5
10
Days
Control
TS-1
TS-1 + Comp.2


CFPAC-1
Relative Tumor Volume
3.5
3
2.5
2
1.5
1
0.5
0
0
5
10
15
Days
*
Control
TS-1
TS-1 + Comp.2


[Figure 8]


20
15
10
5
0
Relative tumor volume
*
*
*
*
Control
Compound 2(1200)
0
150
300
600
1200
TS-1(8.3) + Compound 2

[Figure 9]


100.0
10.0
1.0
0.1
Relative tumor volume
0
10
20
30
Days
***
Control
TS-1(18)
TS-1(18)+Compound 2(6.25)
TS-1(18)+Compound 2(12.5)
TS-1(18)+Compound 2(25)
TS-1(18)+Compound 2(50)
TS-1(18)+Compound 2(100)

[Figure 10]


Relative tumor volume
Days
Control
Capecitabine(160)
Capecitabine(160) + Comp.2(600)
Capecitabine(160) + Comp.2(1200)
Capecitabine(160) + Comp.2(1600)
Capecitabine(359)
Capecitabine(359) + Comp.2(75)
Capecitabine(359) + Comp.2(300)
Capecitabine(359) + Comp.2(600)
Capecitabine(809)
Capecitabine(809) + Comp.2(75)